Association Between 5-Alpha Reductase Inhibitor Use and The Risk of Depression: A Meta-Analysis
Urology Journal,
Vol. 18 No. 02 (2021),
3 May 2021
,
Page 144-150
https://doi.org/10.22037/uj.v18i02.5866
Abstract
Purpose: To explore the association between 5α-reductase inhibitors (5ARIs) use and risk of depression based on published literature through a meta-analysis.
Materials and methods: A comprehensive literature search was conducted by searching Pubmed, Embase,
Cochrane Library, CBM, CNKI, and VIP databases up to June, 2019. Summarized risk ratios (RRs) with 95%
confidence intervals (CIs) were calculated to evaluate the strength of association between 5ARIs and depression. Subgroup analyses were performed according to population, 5ARI types, degree of depression, and publication date. Registered in PROSPERO under number CRD42018096147.
Results: A total of 6 clinical studies with 265672 participants were included in our meta-analysis. The application
of 5ARIs could significantly increase the risk of depression based on both pooled unadjusted (95% CI: 1.28-2.78,
RR = 1.89, P = .001) and multivariable adjusted RRs (95% CI: 1.01-1.17, RR = 1.09, P = .03). In subgroup analyses,
dutasteride was associated with depression significantly (95% CI: 1.37-1.70, RR = 1.53, P < .001), while
finasteride was not. As to the degree of depression, 5ARIs mainly caused mild depression (95% CI: 1.91-2.33, RR
= 2.11, P < .001), instead of moderate or severe depression.
Conclusion: We concluded that 5ARIs could potentially increase the risk of depression. Clinicians need to carefully consider the use of 5ARIs for benign prostatic hyperplasia and androgenic alopecia patients, especially those exhibiting risk factors for depression or those who have a previous history of depression. More studies with larger sample size and comprehensive study design are needed to further verify our outcomes.
- Association
- 5a-reductase inhibitors
- Depression
- Meta-analysis
How to Cite
References
Gravas S, Cornu JN, Drake MJ, et al. European Association of Urology guidelines on treatment of non-neurogenic male LUTS 2017. Available at: http://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/. Accessed January 20, 2018.
McVary KT, Roehrborn CG, Avins AL, et al. American Urological Association guidelines statement on management of Benign Prostatic Hyperplasia (BPH) 2014. Available at: http://www.auanet.org/guidelines/benign-prostatic-hyperplasia-(2010-reviewed-and-validity-confirmed-2014). Accessed January 20, 2018.
Traish AM. 5α-reductases in human physiology: an unfolding story. Endocr Pract. 2012; 18: 965-75.
McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003; 349: 2387-98.
Naslund MJ, Miner M. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Clin Ther. 2007; 29: 17.
Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010; 57: 123.
Rahimi-Ardabili B, Pourandarjani R, Habibollahi P, Mualeki A. Finasteride induced depression: a prospective study. BMC Clin Pharmacol. 2006; 6: 7.
Irwig MS. Depressive symptoms and suicidal thoughts among former users of finasteride with persistent side effects. J Clin Psychiatry. 2012; 73: 1220-3.
Traish AM, Mulgaonkar A, Giordano N. The dark side of 5areductase inhibitors’ therapy: sexual dysfunction, high Gleason grade prostate cancer and depression. Korean J Urol. 2014; 55: 367-79.
Welk B, McArthur E, Ordon M, Anderson KK, Hayward J, Dixon S. Association of Suicidality and Depression With 5α-Reductase Inhibitors. JAMA Intern Med. 2017; 177: 683-91.
Hagberg KW, Divan HA, Nickel JC, Jick SS. Risk of Incident Antidepressant-Treated Depression Associated with Use of 5α-Reductase Inhibitors Compared with Use of α-Blockers in Men with Benign Prostatic Hyperplasia: A Population-Based Study Using the Clinical Practice Research Datalink. Pharmacotherapy. 2017; 37: 517-27.
Altomare G, Capella GL. Depression circumstantially related to the administration of finasteride for androgenetic alopecia. J Dermatol. 2002; 29: 665-9.
Rahimi-Ardabili B, Pourandarjani R, Habibollahi P, Mualeki A. Finasteride induced depression: a prospective study. BMC Clin Pharmacol. 2006; 6: 7.
Melcangi RC, Santi D, Spezzano R, et al. Neuroactive steroid levels and psychiatric and andrological features in post-finasteride patients. J Steroid Biochem Mol Biol. 2017; 171: 229-35.
Kurahashi N, Iwasaki M, Sasazuki S, Otani T, Inoue M, Tsugane S. Soy product and isoflavone consumption in relation to prostate cancer in Japanese men. Cancer Epidemiol Biomarkers Prev. 2007; 16: 538-45.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25: 603-5.
Higgins J, Thomas J (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 6. The Cochrane Collaboration. Available at: https://training.cochrane.org/handbook. Accessed May 7, 2020.
Higgins JP Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327: 557-60.
Pietrzyk B, Olszanecka-Glinianowicz M, Owczarek A, et al. Depressive symptoms in patients diagnosed with benign prostatic hyperplasia. Int Urol Nephrol. 2015; 47: 431-40.
Unger JM, Till C, Thompson IM Jr, et al. Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2016; 108. pii: djw168.
Catalano A, Martino G, Bellone F, et al. Neuropsychological Assessment in Elderly Men with Benign Prostatic Hyperplasia Treated with Dutasteride. Clin Drug Investig. 2019; 39: 97-102.
Clifford GM, Farmer RDT. Drug or symptom-induced depression in men treated with alpha1-blockers for benign prostatic hyperplasia? A nested case-control study. Pharmacother Drug Saf. 2002; 11: 55-61.
Traish AM, Melcangi RC, Bortolato M, Garcia-Segura LM, Zitzmann M. Adverse effects of 5α-reductase inhibitors: What do we know, don’t know, and need to know? Rev Endocr Metab Disord. 2015; 16:177-98.
Celec P, Ostatníková D, Hodosy J. On the effects of testosterone on brain behavioral functions. Front Neurosci. 2015; 9: 1-17.
Paul SM, Purdy RH. Neuroactive steroids. FASEB J. 1992; 6: 2311-22.
Pinacho-Garcia LM, Valdez RA, Navarrete A, Cabeza M, Segovia J, Romano MC. The effect of finasteride and dutasteride on the synthesis of neurosteroids by glioblastoma cells. Steroids. 2020; 155:108556.
Litim N, Morissette M, Caruso D, Melcangi RC, Di Paolo T. Effect of the 5α-reductase enzyme inhibitor dutasteride in the brain of intact and parkinsonian mice. J Steroid Biochem Mol Biol. 2017; 174:242-56.
Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004; 89: 2179-84.
Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science. 1986; 232: 1004-7.
Melcangi RC, Caruso D, Abbiati F, et al. Neuroactive steroid levels are modified in cerebrospinal fluid and plasma of post-finasteride patients showing persistent sexual side effects and anxious/depressive symptomatology. J Sex Med. 2013; 10: 2598-603.
Uzunova V, Sheline Y, Davis JM, et al. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA. 1998; 95: 3239-44.
Romeo E, Ströhle A, Spalletta G, et al. Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiatry. 1998; 155: 910-13.
Rhodes ME, Frye CA. Inhibiting progesterone metabolism in the hippocampus of rats in behavioral estrus decreases anxiolytic behaviors and enhances exploratory and antinociceptive behaviors. Cogn Affect Behav Neurosci. 2001; 1: 287-96.
Frye CA, Walf AA. Changes in progesterone metabolites in the hippocampus can modulate open field and forced swim test behavior of proestrous rats. Horm Behav. 2002; 41: 306-15.
Djernes JK. Prevalence and predictors of depression in populations of elderly: a review. Acta Psychiatr Scand. 2006; 113: 372-87.
- Abstract Viewed: 163 times
- 5866/pdf Downloaded: 114 times